FULVESTRANT AND
ELACESTRANT (SERDs)
SERDs eliminate the oestrogen receptor from the cancer cell rather than simply blocking it β a mechanistically distinct approach from tamoxifen and aromatase inhibitors that provides options when those agents have failed. Elacestrant, the first oral SERD, has specifically transformed outcomes for the ESR1-mutant breast cancer subgroup.
analyticsAt a Glance
- check_circleFulvestrant (Faslodex) binds ER with 100Γ greater affinity than tamoxifen and triggers its proteasomal degradation
- check_circleElacestrant (Orserdu) β the first oral SERD β is approved for ESR1-mutant ER+/HER2β metastatic breast cancer post-CDK4/6 inhibitor
- check_circleThe EMERALD trial showed elacestrant doubled PFS vs standard ET (ESR1-mutant subgroup: 3.8 vs 1.9 months median PFS)
- check_circleNext-generation SERDs β camizestrant, giredestrant, imlunestrant β are in Phase III trials and may further improve outcomes
What Is a SERD and How Is It Different from Tamoxifen?
Tamoxifen is a SERM β a selective oestrogen receptor modulator. It binds the oestrogen receptor and blocks oestrogen from activating it, but does not destroy the receptor itself. A small conformational change in the ER induced by tamoxifen allows partial agonist activity β contributing to the endometrial stimulation and bone-protective effects characteristic of tamoxifen.
βTamoxifen says 'no entry' at the oestrogen receptor door. Fulvestrant tears the door off entirely. Elacestrant does the same thing in a pill rather than an injection.β
How SERDs Work: Receptor Degradation
SERDs bind the oestrogen receptor with high affinity and induce a conformational change that prevents the receptor from dimerising and marks it for ubiquitin-proteasomal degradation. The net effect is elimination of the oestrogen receptor from the cancer cell β removing the signalling machinery entirely rather than just blocking it. This complete abolition of ER signalling is particularly important in tumours that have acquired ESR1 mutations that make the ER constitutively active (active without oestrogen).
Why SERDs Matter After CDK4/6 Inhibitor Progression
After progression on a CDK4/6 inhibitor + AI, the oestrogen receptor pathway remains the primary therapeutic target in ER+/HER2β metastatic breast cancer. ESR1 mutations β acquired under the selection pressure of prior aromatase inhibitor therapy β make standard AIs ineffective because they cannot suppress a constitutively active mutant ER. SERDs degrade the mutant ER protein regardless of its activation state β restoring the ability to target the receptor even in ESR1-mutant disease.
Fulvestrant vs Elacestrant: A Practical Comparison
Fulvestrant and elacestrant share the SERD mechanism but differ critically in route of administration, ESR1-mutation specificity, and the treatment contexts where each is most commonly used.
| Parameter | Fulvestrant (Faslodex) | Elacestrant (Orserdu) |
|---|---|---|
| Route | Intramuscular injection β 500 mg Γ 2 injections into gluteal muscles, monthly | Oral β 345 mg tablet once daily with food |
| Approval | FDA 2002; EMA 2004 β widely available globally | FDA January 2023; EMA 2023; Asia β regulatory submissions ongoing |
| ESR1 specificity | Active in ESR1-wild-type and ESR1-mutant but less differential benefit in mutant | Specifically indicated for ESR1-mutant disease β greatest PFS benefit in this subgroup |
| Primary approved use | 2nd-line metastatic ER+/HER2β after AI failure (FALCON trial); 1st line with palbociclib (PALOMA-3) | 2nd line+ metastatic ER+/HER2β after progression on β₯1 endocrine therapy (including CDK4/6i) |
| Key trial | FALCON (fulvestrant vs anastrozole, 1st line); PALOMA-3 (+ palbociclib, 2nd line) | EMERALD (elacestrant vs standard ET in 2nd+ line post-CDK4/6i) |
| Efficacy in ESR1-mutant | Modest improvement over AI; reduced efficacy in ESR1-mutant vs wild-type | Significantly better than fulvestrant or AI in ESR1-mutant: PFS HR 0.55 vs 0.86 in wild-type |
| Common side effects | Injection site reactions; hot flushes; arthralgia; nausea; headache | Nausea (35%); dyslipidaemia/elevated lipids; fatigue; vomiting; constipation; arthralgias |
| Availability in Asia | Widely available in China and India β generics available | Innovator product β regulatory approval pending in China/India; access via specialist programmes |
The EMERALD Trial: How Elacestrant Changed the ESR1-Mutant Landscape
EMERALD is the Phase III trial that established elacestrant as the first approved oral SERD and the first drug to demonstrate improved survival specifically in ESR1-mutant metastatic breast cancer.
EMERALD Trial β PFS: Elacestrant vs Standard Endocrine Therapy (Post-CDK4/6i)
Source: Bidard FC et al., Lancet Oncol 2022; Bardia A et al., NEJM 2023. Standard ET = fulvestrant or AI chosen by investigator
- Median PFS: Elacestrant (ESR1-mutant subgroup)3.8 mo
- Median PFS: Standard ET (ESR1-mutant subgroup)1.9 mo
- Median PFS: Elacestrant (all patients β ITT)2.8 mo
- Median PFS: Standard ET (all patients β ITT)1.9 mo
- 1-year PFS rate: Elacestrant (ESR1-mutant)26.8%
- 1-year PFS rate: Standard ET (ESR1-mutant)8.2%
Next-Generation Oral SERDs: What Is Coming
Elacestrant is the first approved oral SERD β but it is unlikely to be the last. Several next-generation oral SERDs are in late-phase clinical development with different pharmacological profiles and combination strategies.
Camizestrant (AstraZeneca / SERENA-4 and SERENA-6 trials)
Camizestrant is a next-generation oral SERD with near-complete ER degradation and activity in CDK4/6i-naive and -pretreated settings. The SERENA-4 trial (Phase III) is evaluating camizestrant vs anastrozole Β± palbociclib as first-line therapy. SERENA-6 is evaluating camizestrant as a switch therapy when ESR1 mutation is detected by ctDNA during AI + CDK4/6i treatment β before clinical progression.
Giredestrant (Roche / persevERA trial)
Giredestrant showed initial Phase II activity but disappointing Phase III results in the persevERA trial (giredestrant + palbociclib vs letrozole + palbociclib first-line) β the trial did not meet its PFS endpoint. Despite this setback, giredestrant is being studied in other combinations and settings.
Imlunestrant (Eli Lilly / EMBER-3 trial)
Imlunestrant is another oral SERD with Phase III data expected. The EMBER-3 trial evaluates imlunestrant alone and in combination with abemaciclib in the post-CDK4/6i setting. Early Phase I/II data show activity in ESR1-mutant disease and a profile that may complement CDK4/6 inhibitor combination.
Key SERD Numbers
Reference figures from the pivotal SERD trials.
- 500 mgFulvestrant monthly dose (split between 2 injections)The CONFIRM trial established 500 mg as superior to 250 mg β 500 mg monthly is the standard dose. Lower doses are sub-therapeutic and should not be used.
- HR 0.55Hazard ratio for elacestrant in ESR1-mutant subgroupA 45% relative reduction in PFS hazard vs standard ET β the most robust evidence for any agent in the ESR1-mutant post-CDK4/6i setting.
- 30β40%ESR1 mutation frequency after prior AI therapyESR1 mutations are rare at initial diagnosis but selected for under aromatase inhibitor therapy β present in 30β40% of patients who have received prior AI treatment.
- ctDNATesting method for ESR1 mutations before elacestrantLiquid biopsy (ctDNA) in blood is the recommended test β more sensitive and less invasive than repeat tumour biopsy, and captures tumour heterogeneity across all lesions.
More from the Hormone Therapy Resource Library
Continue exploring advanced ER+ breast cancer treatment β from CDK4/6 inhibitors to ESR1 mutations and PIK3CA-targeted therapy.
- CDK4/6 Inhibitors: Palbociclib, Ribociclib, Abemaciclib Explained
- ESR1 Mutations in Breast Cancer: What They Mean and How They Change Treatment
- Alpelisib (Piqray) for PIK3CA-Mutated Breast Cancer
- Aromatase Inhibitors: Letrozole, Anastrozole, and Exemestane
- Tamoxifen: Side Effects, CYP2D6 Interactions, and Monitoring
- Hormone Therapy for Breast Cancer β Complete Guide
Frequently Asked Questions
Common questions from patients about SERDs and how to access them.
About Fulvestrant and Elacestrant
Fulvestrant involves gluteal injections β can I administer these at home?
Fulvestrant 500 mg monthly is administered as two 250 mg injections into the left and right gluteal muscles β delivered by a nurse or physician, not self-administered at home. Each injection is a relatively slow infusion (approximately 1β2 minutes per injection) using a 23-gauge needle. Most patients find the injections uncomfortable but manageable. At oncology day units in China and India accessible via CancerFax, fulvestrant injections are administered as a brief scheduled appointment, typically alongside clinical review. The injection site reactions β local soreness, occasional bruising β resolve within a few days of each dose.
Is elacestrant available in China or India?
Elacestrant (Orserdu) received FDA approval in January 2023 and EMA approval in September 2023. Regulatory submissions are underway in China and other Asian markets, but full approval and broad availability in China and India were not yet established as of late 2024. For patients in China or India who need access to elacestrant before local approval, CancerFax can advise on compassionate use pathways, named patient import, or referral to centres participating in ongoing clinical trials involving elacestrant or next-generation SERDs. The situation is evolving β contact CancerFax for the most current access information for your specific location.
Do I need a liquid biopsy to test for ESR1 mutation before receiving elacestrant?
Yes β ESR1 mutation testing is required before elacestrant is prescribed, as the drug's most compelling evidence is in the ESR1-mutant population. A liquid biopsy (blood ctDNA test) is the preferred method β it is less invasive than a repeat tissue biopsy and captures mutations across all metastatic lesions simultaneously. ESR1 mutations typically arise under the selection pressure of prior aromatase inhibitor therapy and may not be present in the archival primary tumour biopsy. A blood-based ctDNA test at progression after prior AI + CDK4/6i therapy is the appropriate time to test. Ensure the test includes the most common ESR1 activating mutations: Y537S, D538G, L536R, E380Q, and related codons.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About SERD Treatment for Metastatic Breast Cancer?
CancerFax connects patients with specialist breast oncologists who can review your ESR1 mutation status, prior treatment history, and current disease burden to assess whether fulvestrant, elacestrant, or a next-generation SERD trial is the most appropriate next step.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.